ArticlePreventive medicine reports2025
Glucagon-like peptide-1 receptor agonists and suicide risk in individuals with diabetes and Cannabis use disorder.
Article in Preventive medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Association Between Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.Diabetes, obesity & metabolism · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The current study is to examine the association between GLP-1 receptor agonist (GLP-1 RA) use and suicide attempt risk in individuals with type 2 diabetes mellitus (T2DM), including those with comorbid cannabis use disorder (CUD). Methods: We conducted a retrospective study using the TriNetX Research Network. Adults aged 30-85 years with a diagnosis of T2DM were categorized by GLP-1 RA exposure and CUD sourced from over 20 countries across the Americas, Europe-Middle East-Africa, and Asia-Pacific from 2003 to 2023. Individuals with a prior diagnosis of suicidal ideation were excluded. The primary outcome was a new diagnosis of suicide attempt within one year. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs), controlling for age, sex, depression, body mass index, and glycated hemoglobin A1c (HbA1c) levels. Kaplan-Meier curves were used to visualize cumulative risk. Results: Among 6,424,228 individuals with T2DM, GLP-1 RA use was associated with significantly lower risk of suicide attempt compared to unexposed individuals (aHR: 0.63; 95 % CI: 0.47,0.85). In contrast, patients with CUD exhibited markedly elevated risk (aHR: 5.50; 95 % CI: 4.39,6.89). This elevated risk persisted among those concurrently using GLP-1 RAs and diagnosed with CUD (aHR: 5.75; 95 % CI: 3.42,9.69). No significant risk reduction was observed among CUD patients using GLP-1 RAs compared to those not using them (aHR: 1.00; 95 % CI 0.37-2.69). Conclusions: The inverse association between GLP-1 RAs and suicide attempt was attenuated among cannabis users. These findings underscore the importance of addressing substance use when assessing psychiatric risk in diabetes care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.